Literature DB >> 6299963

Monoclonal antibodies against three major glycoproteins of varicella-zoster virus.

C Grose, D P Edwards, W E Friedrichs, K A Weigle, W L McGuire.   

Abstract

Varicella-zoster virus (VZV) codes for three prominent glycoproteins--gp62, gp98, and gp118--in infected cell cultures. To characterize individually these known immunogens, we first inoculated BALB/c mice with crude VZV extracts, produced hybridoma cultures by Köhler-Milstein cell-fusion technology, and screened culture supernatants by indirect immunofluorescence for reactivity directed against unfixed VZV-infected cells (FAMA assay). Supernatants from five independently derived and subcloned hybridomas with a high VZV-FAMA titer but no reactivity against either uninfected or herpes simplex virus-infected cells were further analyzed by immunoprecipitation of [3H]fucose-labeled and detergent-solubilized VZV antigen preparations. Fractionation of the precipitates by sodium dodecyl sulfate-polyacrylamide gel electrophoresis demonstrated that four monoclonal antibodies reacted with both gp62 and gp98, and one precipitated only gp118. The profiles were unchanged whether performed under reducing or nonreducing conditions. When assayed for neutralizing activity, the secretory product of the single anti-gp118 hybridoma, but not the supernatants from the four anti-gp62/gp98 clones, inhibited VZV plaque formation by greater than 80%. Thus, at least one of the glycosylated antigens detected by the FAMA assay is a determinant which elicits neutralizing activity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6299963      PMCID: PMC264858          DOI: 10.1128/iai.40.1.381-388.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Varicella-zoster virus: isolation and propagation in human melanoma cells at 36 and 32 degrees C.

Authors:  C Grose; P A Brunel
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

Review 3.  Use of staphylococcal protein A as an immunological reagent.

Authors:  J W Goding
Journal:  J Immunol Methods       Date:  1978       Impact factor: 2.303

4.  Zoster immune globulin. A further assessment.

Authors:  A A Gershon; S Steinberg; P A Brunell
Journal:  N Engl J Med       Date:  1974-01-31       Impact factor: 91.245

5.  Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence.

Authors:  V Williams; A Gershon; P A Brunell
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

6.  Type-specific protein in herpes simplex virus envelope reacts with neutralising antibody.

Authors:  K L Powell; A Buchan; C Sim; D H Watson
Journal:  Nature       Date:  1974-05-24       Impact factor: 49.962

7.  The preparation of 'monoprecipitin' antisera to herpes virus specific antigens.

Authors:  D H Watson; P Wildy
Journal:  J Gen Virol       Date:  1969-03       Impact factor: 3.891

8.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels.

Authors:  W M Bonner; R A Laskey
Journal:  Eur J Biochem       Date:  1974-07-01

9.  Complement-enhanced neutralizing antibody response to varicella-zoster virus.

Authors:  C Grose; B J Edmond; P A Brunell
Journal:  J Infect Dis       Date:  1979-04       Impact factor: 5.226

10.  Sodium dodecyl sulfate in protein chemistry.

Authors:  T V Waehneldt
Journal:  Biosystems       Date:  1975-03       Impact factor: 1.973

View more
  45 in total

1.  Delayed biosynthesis of varicella-zoster virus glycoprotein C: upregulation by hexamethylene bisacetamide and retinoic acid treatment of infected cells.

Authors:  Johnathan Storlie; Wallen Jackson; Jennifer Hutchinson; Charles Grose
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Incorporation of three endocytosed varicella-zoster virus glycoproteins, gE, gH, and gB, into the virion envelope.

Authors:  Lucie Maresova; Tracy Jo Pasieka; Elizabeth Homan; Erick Gerday; Charles Grose
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Neutralizing antibodies specific for glycoprotein H of herpes simplex virus permit viral attachment to cells but prevent penetration.

Authors:  A O Fuller; R E Santos; P G Spear
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

4.  Varicella-zoster virus glycoprotein oligosaccharides are phosphorylated during posttranslational maturation.

Authors:  C A Gabel; L Dubey; S P Steinberg; D Sherman; M D Gershon; A A Gershon
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

5.  Characterization of neutralizing epitopes of varicella-zoster virus glycoprotein H.

Authors:  Yasushi Akahori; Kazuhiro Suzuki; Tohru Daikoku; Masae Iwai; Yoshihiro Yoshida; Yoshizo Asano; Yoshikazu Kurosawa; Kimiyasu Shiraki
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

6.  Discordant varicella-zoster virus glycoprotein C expression and localization between cultured cells and human skin vesicles.

Authors:  Johnathan Storlie; John E Carpenter; Wallen Jackson; Charles Grose
Journal:  Virology       Date:  2008-10-26       Impact factor: 3.616

7.  Glycoprotein gp118 of varicella-zoster virus: purification by serial affinity chromatography.

Authors:  W E Friedrichs; C Grose
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

8.  Phosphorylation of varicella-zoster virus open reading frame (ORF) 62 regulatory product by viral ORF 47-associated protein kinase.

Authors:  T I Ng; L Keenan; P R Kinchington; C Grose
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

Review 9.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

10.  New variant of varicella-zoster virus.

Authors:  Graham A Tipples; Gwen M Stephens; Chris Sherlock; Margrit Bowler; Benny Hoy; Darrel Cook; Charles Grose
Journal:  Emerg Infect Dis       Date:  2002-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.